Last reviewed · How we verify
Tigecycline once daily regimen
Tigecycline once daily regimen, developed by Air Force Specialized Hospital in Cairo, Egypt, is a marketed antibiotic with a key composition patent expiring in 2028. The drug's key strength lies in its once-daily dosing regimen, which may improve patient compliance compared to more frequent dosing schedules. The primary risk is the lack of revenue data and key trial results, which could limit its market adoption and competitive positioning.
At a glance
| Generic name | Tigecycline once daily regimen |
|---|---|
| Sponsor | Air Force Specialized Hospital, Cairo, Egypt |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Clinical Effectiveness of a Once-daily Regimen of Tigecycline Compared to the Standard Regimen (PHASE4)
- Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: